MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

HCV-IN-7 hydrochloride

CAS No. : 1449756-87-9

MCE 站：HCV-IN-7 hydrochloride

产品活性：HCV-IN-7 hydrochloride 是一种口服有效的泛基因型 HCV NS5A 抑制剂，IC₅₀ 为 3-47 pM。HCV-IN-7 hydrochloride 具有优良的泛基因型和良好的药代动力学特征，并具有良好的肝脏吸收能力。HCV-IN-7 hydrochloride 具有抗病毒活性。

研究领域：Anti-infection

作用靶点：HCV

In Vitro: HCV-IN-7 hydrochloride inhibits GT1b (IC₅₀=12 pM), GT2a (IC₅₀=5 pM), GT1a (IC₅₀=27 pM), GT3a (IC₅₀=47 pM), GT4a (IC₅₀=3 pM), GT6a (IC₅₀=28 pM).
HCV-IN-7 hydrochloride (10 ?M) has 12%, 42%, 12% inhibition for CYP2D6, CYP2C9, CYP3A4, respectively.
HCV-IN-7 hydrochloride (10 ?M) has cytotoxicity of 14%, 22%, 36% in Huh7, HepG2 and HEK cells, respectively.
HCV-IN-7 hydrochloride has a less complex central tricyclic core as novel and potent pan-genotypic NS5A inhibitors with good pharmacokinetic profile.

In Vivo: HCV-IN-7 hydrochloride (iv; 1 mg/kg) has a T_1/2 of 2 hours, CL of 11 mL/min/kg, and a V_ss of 2 L/kg for rats.
HCV-IN-7 hydrochloride (po; 10 mg/kg) has a C_{max of 1 μM and an AUClast of 6 μM for rats.
HCV-IN-7 hydrochloride (iv; 1 mg/kg) has a T1/2 of 4 hours, CL of 6 mL/min/kg, and a Vss of 2 L/kg for dog.
HCV-IN-7 hydrochloride (po; 10 mg/kg) has a Cmax of 5 μM and an AUClast of 49 μM for dog.}

相关产品：Resiquimod  |  Honokiol  |  Ribavirin  |  Deferiprone  |  U18666A  |  AG-1478  |  EIDD-1931  |  Artemisinin  |  NIM811  |  Alisporivir  |  Myriocin  |  Mizoribine  |  Merimepodib  |  NHC-triphosphate  |  PSI-7409  |  Peretinoin  |  BLT-1  |  Celgosivir hydrochloride  |  Clemizole hydrochloride  |  Gentiopicroside  |  NM107  |  ITX5061  |  Deapioplatycodin D  |  KIN1408  |  Oglufanide  |  PSI-6130  |  RO-9187  |  RO8191  |  Taribavirin hydrochloride

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。